Retevmo

E561040

Retevmo is a targeted cancer therapy (selpercatinib) used to treat tumors driven by RET gene alterations, including certain lung and thyroid cancers.

All labels observed (1)

Label Occurrences
Retevmo canonical 4

How this entity was disambiguated

Statements (46)

Predicate Object
instanceOf pharmaceutical drug ⓘ
targeted cancer therapy ⓘ
tyrosine kinase inhibitor ⓘ
approvedBy U.S. Food and Drug Administration ⓘ
approvedIn European Union ⓘ
Japan ⓘ
United States ⓘ
belongsToPharmacologicClass selective RET inhibitor ⓘ
contraindicatedWith severe hypersensitivity to selpercatinib ⓘ
developedBy Eli Lilly and Company ⓘ
hasActiveIngredient selpercatinib ⓘ
hasApprovalType FDA accelerated approval ⓘ
hasATCCode L01EX19 ⓘ
hasBlackBoxWarning hepatotoxicity ⓘ
hasCommonAdverseEffect constipation ⓘ
diarrhea ⓘ
dry mouth ⓘ
edema ⓘ
elevated liver enzymes ⓘ
fatigue ⓘ
hypertension ⓘ
hasDosageForm capsule ⓘ
hasDrugInteraction strong CYP3A inducers ⓘ
strong CYP3A inhibitors ⓘ
hasHalfLife approximately 32 hours ⓘ
hasInternationalNonproprietaryName selpercatinib ⓘ
hasPregnancyRisk may cause fetal harm ⓘ
hasRouteOfAdministration oral ⓘ
hasWarning QT interval prolongation ⓘ
hemorrhagic events ⓘ
hypersensitivity reactions ⓘ
hypertension ⓘ
risk of impaired wound healing ⓘ
indicatedFor RET fusion-positive non-small cell lung cancer ⓘ
RET fusion-positive thyroid cancer ⓘ
RET-mutant medullary thyroid cancer ⓘ
advanced RET fusion-positive thyroid carcinoma ⓘ
advanced medullary thyroid carcinoma with RET mutation ⓘ
metastatic non-small cell lung cancer with RET gene fusion ⓘ
mechanismOfAction selective RET kinase inhibition ⓘ
metabolizedBy CYP3A4 ⓘ
regulatesPathway RET signaling pathway ⓘ
requiresCompanionDiagnostic RET gene alteration testing ⓘ
targetsGene RET ⓘ
usedIn adult patients ⓘ
pediatric patients 12 years and older ⓘ

How these facts were elicited

Referenced by (4)

Full triples — surface form annotated when it differs from this entity's canonical label.

Loxo Oncology → secondMajorProductMarketedName → Retevmo ⓘ
subject linked to: Loxo Oncology (acquired)
selpercatinib → hasBrandName → Retevmo ⓘ
LOXO-292 → hasSynonym → Retevmo ⓘ
LOXO-292 → hasBrandName → Retevmo ⓘ